MeiraGTx Holdings plc Key Executives
This section highlights MeiraGTx Holdings plc's key executives, including their titles and compensation details.
Find Contacts at MeiraGTx Holdings plc
(Showing 0 of )
MeiraGTx Holdings plc Earnings
This section highlights MeiraGTx Holdings plc's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
$6.82
Stock Price
$537.79M
Market Cap
381
Employees
New York, NY
Location
Financial Statements
Access annual & quarterly financial statements for MeiraGTx Holdings plc, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $33.28M | $14.02M | $15.92M | $37.70M | $15.56M |
| Cost of Revenue | $23.79M | $- | $8.72M | $7.87M | $- |
| Gross Profit | $9.49M | $14.02M | $7.20M | $29.83M | $15.56M |
| Gross Profit Ratio | 28.51% | 100.00% | 45.21% | 79.10% | 100.00% |
| Research and Development Expenses | $119.48M | $103.78M | $85.72M | $67.13M | $33.91M |
| General and Administrative Expenses | $54.22M | $47.29M | $46.55M | $43.77M | $44.21M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $54.22M | $47.29M | $46.55M | $43.77M | $44.21M |
| Other Expenses | $- | $- | $361.00K | $-434.00K | $- |
| Operating Expenses | $173.70M | $151.08M | $132.28M | $110.89M | $78.12M |
| Cost and Expenses | $197.49M | $151.08M | $132.28M | $110.89M | $78.12M |
| Interest Income | $4.14M | $2.27M | $777.00K | $212.00K | $1.28M |
| Interest Expense | $13.27M | $13.24M | $4.95M | $288.00K | $139.20K |
| Depreciation and Amortization | $12.68M | $13.73M | $8.72M | $7.87M | $4.17M |
| EBITDA | $-121.84M | $-57.05M | $-115.95M | $-71.40M | $-53.68M |
| EBITDA Ratio | -366.11% | -407.02% | -725.99% | -193.58% | -393.75% |
| Operating Income | $-164.21M | $-137.06M | $-116.36M | $-73.19M | $-62.55M |
| Operating Income Ratio | -493.44% | -977.82% | -730.87% | -194.14% | -401.94% |
| Total Other Income Expenses Net | $16.42M | $53.03M | $-13.26M | $-6.37M | $4.56M |
| Income Before Tax | $-147.79M | $-84.03M | $-129.62M | $-79.56M | $-57.99M |
| Income Before Tax Ratio | -444.10% | -599.46% | -814.16% | -211.03% | -372.63% |
| Income Tax Expense | $- | $- | $13.26M | $-7.58M | $-4.03M |
| Net Income | $-147.79M | $-84.03M | $-142.88M | $-71.98M | $-53.96M |
| Net Income Ratio | -444.10% | -599.46% | -897.46% | -190.91% | -346.72% |
| EPS | $-2.12 | $-1.49 | $-3.16 | $-1.63 | $-1.43 |
| EPS Diluted | $-2.12 | $-1.49 | $-3.16 | $-1.63 | $-1.43 |
| Weighted Average Shares Outstanding | 69.82M | 56.49M | 45.18M | 44.14M | 37.72M |
| Weighted Average Shares Outstanding Diluted | 69.82M | 56.49M | 45.18M | 44.14M | 37.72M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.39M | $10.91M | $282.00K | $697.00K | $2.04M | $5.10M | $3.54M | $3.33M | $-5.29M | $4.82M | $10.76M | $5.63M | $21.04M | $6.95M | $5.12M | $4.59M | $3.79M | $5.09M | $2.47M | $4.21M |
| Cost of Revenue | $5.31M | $11.98M | $3.22M | $3.27M | $3.91M | $3.48M | $3.25M | $3.09M | $- | $2.03M | $2.08M | $2.12M | $16.66M | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $16.08M | $-1.07M | $-2.94M | $-2.58M | $-1.87M | $1.62M | $293.00K | $242.00K | $-5.29M | $2.79M | $8.67M | $3.52M | $4.38M | $6.95M | $5.12M | $4.59M | $3.79M | $5.09M | $2.47M | $4.21M |
| Gross Profit Ratio | 28.51% | -9.85% | -1042.60% | -369.90% | -91.80% | 31.80% | 8.30% | 7.30% | 100.00% | 57.90% | 80.60% | 62.40% | 20.80% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research and Development Expenses | $23.98M | $26.24M | $34.93M | $34.32M | $33.67M | $27.86M | $19.94M | $22.32M | $21.77M | $16.86M | $24.00M | $23.10M | $13.62M | $21.61M | $15.19M | $16.71M | $5.00M | $4.63M | $16.20M | $8.08M |
| General and Administrative Expenses | $17.09M | $12.72M | $11.26M | $13.15M | $12.12M | $10.01M | $12.39M | $12.77M | $14.00M | $10.76M | $10.52M | $11.27M | $15.55M | $7.89M | $10.41M | $9.92M | $12.01M | $8.90M | $11.50M | $11.81M |
| Selling and Marketing Expenses | $3.27M | $- | $- | $-3.27M | $-3.91M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $20.36M | $12.72M | $11.26M | $9.87M | $8.21M | $10.01M | $12.39M | $12.77M | $14.00M | $10.76M | $10.52M | $11.27M | $15.55M | $7.89M | $10.41M | $9.92M | $12.01M | $8.90M | $11.50M | $11.81M |
| Other Expenses | $- | $- | $- | $- | $446.00K | $- | $-1.00K | $54.00K | $46.55M | $-34.00K | $252.00K | $397.00K | $43.77M | $- | $- | $- | $44.21T | $- | $- | $- |
| Operating Expenses | $44.35M | $38.97M | $46.19M | $44.19M | $41.88M | $37.87M | $32.33M | $35.09M | $35.77M | $27.62M | $34.52M | $34.37M | $29.17M | $29.50M | $25.60M | $26.63M | $17.01M | $13.52M | $27.70M | $19.89M |
| Cost and Expenses | $52.88M | $50.95M | $46.19M | $47.47M | $45.79M | $37.87M | $32.33M | $35.09M | $35.77M | $27.62M | $34.52M | $34.37M | $29.17M | $29.50M | $25.60M | $26.63M | $17.01M | $13.52M | $27.70M | $19.89M |
| Interest Income | $1.03M | $1.19M | $827.00K | $1.10M | $549.00K | $523.00K | $655.00K | $545.00K | $432.00K | $288.00K | $41.00K | $16.00K | $24.00K | $32.00K | $67.00K | $89.00K | $134.14K | $158.35K | $193.60K | $789.37K |
| Interest Expense | $3.41M | $3.36M | $3.25M | $3.25M | $3.45M | $3.38M | $3.35M | $3.06M | $2.90M | $1.89M | $82.00K | $77.00K | $119.00K | $59.00K | $51.00K | $59.00K | $36.06K | $35.14K | $34.05K | $33.97K |
| Depreciation and Amortization | $2.92M | $3.26M | $3.22M | $3.27M | $3.91M | $3.48M | $3.25M | $3.09M | $2.49M | $2.03M | $2.08M | $2.12M | $2.06M | $2.04M | $2.02M | $1.76M | $1.35M | $1.06M | $941.00K | $815.00K |
| EBITDA | $-33.06M | $-32.71M | $-42.14M | $-13.92M | $-39.84M | $-37.44M | $-22.98M | $-24.21M | $-10.64M | $-33.36M | $-31.81M | $-28.85M | $-7.73M | $-23.85M | $-18.02M | $-21.80M | $-9.07M | $-5.33M | $-24.44M | $-14.83M |
| EBITDA Ratio | -366.11% | -299.84% | -14944.68% | -6240.60% | -1953.04% | -563.59% | -702.94% | -934.64% | 714.26% | -425.50% | -198.72% | -472.22% | -28.69% | -294.85% | -359.66% | -439.28% | -309.77% | -141.54% | -973.91% | -334.36% |
| Operating Income | $-31.49M | $-40.04M | $-45.91M | $-46.77M | $-43.75M | $-32.76M | $-28.79M | $-31.76M | $-41.05M | $-22.81M | $-23.76M | $-28.73M | $-8.12M | $-22.55M | $-20.48M | $-22.03M | $-13.22M | $-8.43M | $-25.23M | $-15.68M |
| Operating Income Ratio | -493.44% | -367.01% | -16279.79% | -6710.47% | -2144.80% | -642.01% | -813.14% | -952.61% | 776.38% | -473.59% | -220.82% | -510.10% | -38.61% | -324.63% | -400.37% | -479.48% | -348.97% | -165.57% | -1019.75% | -372.48% |
| Total Other Income Expenses Net | $-7.91M | $711.00K | $-2.71M | $26.33M | $63.97M | $-11.54M | $-796.00K | $1.40M | $13.74M | $-14.48M | $-10.21M | $-2.31M | $-1.79M | $-3.39M | $397.00K | $-1.58M | $2.76M | $2.00M | $-192.30K | $-1.30K |
| Income Before Tax | $-39.40M | $-39.33M | $-48.62M | $-20.44M | $20.21M | $-44.30M | $-29.58M | $-30.36M | $-27.31M | $-37.28M | $-33.97M | $-31.05M | $-9.91M | $-25.95M | $-20.09M | $-23.62M | $-10.46M | $-6.43M | $-25.42M | $-15.68M |
| Income Before Tax Ratio | -444.10% | -360.49% | -17241.13% | -2932.86% | 990.93% | -868.06% | -835.62% | -910.74% | 516.51% | -774.17% | -315.76% | -551.13% | -47.10% | -373.47% | -392.61% | -513.97% | -276.17% | -126.31% | -1027.52% | -372.51% |
| Income Tax Expense | $-3.23M | $- | $- | $3.23M | $-8.40M | $3.38M | $3.35M | $1.66M | $-13.74M | $14.48M | $334.00K | $2.31M | $2.25M | $59.00K | $51.00K | $59.00K | $36.06K | $35.14K | $34.05K | $33.97K |
| Net Income | $-39.40M | $-39.33M | $-48.62M | $-20.44M | $20.21M | $-44.30M | $-29.58M | $-32.03M | $-13.57M | $-51.76M | $-33.97M | $-33.36M | $-9.91M | $-25.95M | $-20.09M | $-23.62M | $-10.46M | $-6.43M | $-25.42M | $-15.68M |
| Net Income Ratio | -444.10% | -360.49% | -17241.13% | -2932.86% | 990.93% | -868.06% | -835.62% | -960.65% | 256.64% | -1074.75% | -315.76% | -592.15% | -47.10% | -373.47% | -392.61% | -513.97% | -276.17% | -126.31% | -1027.52% | -372.51% |
| EPS | $-0.49 | $-0.55 | $-0.76 | $-0.32 | $0.32 | $-0.74 | $-0.53 | $-0.66 | $-0.31 | $-1.16 | $-0.76 | $-0.75 | $-0.22 | $-0.59 | $-0.46 | $-0.54 | $-0.28 | $-0.17 | $-0.69 | $-0.43 |
| EPS Diluted | $-0.49 | $-0.55 | $-0.76 | $-0.32 | $0.32 | $-0.74 | $-0.53 | $-0.66 | $-0.31 | $-1.16 | $-0.76 | $-0.75 | $-0.22 | $-0.59 | $-0.46 | $-0.54 | $-0.28 | $-0.17 | $-0.69 | $-0.43 |
| Weighted Average Shares Outstanding | 69.82M | 71.63M | 64.38M | 64.07M | 63.60M | 59.53M | 55.35M | 48.64M | 44.14M | 44.69M | 44.67M | 44.50M | 44.17M | 44.17M | 44.14M | 43.97M | 37.22M | 37.22M | 36.97M | 36.62M |
| Weighted Average Shares Outstanding Diluted | 69.82M | 71.63M | 64.38M | 64.07M | 63.60M | 59.53M | 55.35M | 48.64M | 44.14M | 44.69M | 44.67M | 44.50M | 44.17M | 44.17M | 44.14M | 43.97M | 37.22M | 37.22M | 36.97M | 36.62M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $103.66M | $129.57M | $115.52M | $137.70M | $209.52M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $103.66M | $129.57M | $115.52M | $137.70M | $209.52M |
| Net Receivables | $707.00K | $23.41M | $29.02M | $35.02M | $38.48M |
| Inventory | $385.00K | $- | $8.13M | $8.10M | $7.08M |
| Other Current Assets | $18.77M | $6.64M | $9.80M | $10.52M | $7.65M |
| Total Current Assets | $123.52M | $159.62M | $154.34M | $183.24M | $272.58M |
| Property Plant Equipment Net | $135.65M | $156.24M | $154.09M | $126.29M | $87.12M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $821.00K | $1.12M | $2.08M | $2.57M | $2.97M |
| Goodwill and Intangible Assets | $821.00K | $1.12M | $2.08M | $2.57M | $2.97M |
| Long Term Investments | $6.75M | $6.77M | $6.33M | $6.66M | $-213.72B |
| Tax Assets | $- | $- | $186.00K | $196.00K | $213.72B |
| Other Non-Current Assets | $3.01M | $3.00M | $1.22M | $1.21M | $1.03M |
| Total Non-Current Assets | $146.23M | $167.12M | $163.90M | $136.92M | $91.12M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $269.75M | $326.74M | $318.24M | $320.16M | $363.70M |
| Account Payables | $23.59M | $16.04M | $16.62M | $15.35M | $7.13M |
| Short Term Debt | $4.05M | $4.19M | $7.77M | $6.75M | $2.58M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $4.83M | $2.93M | $15.12M | $21.82M | $23.54M |
| Other Current Liabilities | $28.32M | $43.92M | $42.56M | $24.21M | $44.43M |
| Total Current Liabilities | $60.78M | $67.08M | $82.07M | $68.13M | $54.15M |
| Long Term Debt | $- | $85.07M | $88.36M | $20.36M | $19.67M |
| Deferred Revenue Non-Current | $- | $34.02M | $27.44M | $43.05M | $49.30M |
| Deferred Tax Liabilities Non-Current | $- | $- | $186.00K | $196.00K | $213.72K |
| Other Non-Current Liabilities | $141.14M | $2.40M | $2.44M | $3.03M | $1.81M |
| Total Non-Current Liabilities | $141.14M | $121.49M | $118.43M | $66.64M | $70.99M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $201.92M | $188.57M | $200.50M | $134.76M | $125.14M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $3.00K | $2.00K | $2.00K | $2.00K | $1.72K |
| Retained Earnings | $-702.02M | $-554.23M | $-470.20M | $-340.59M | $-261.03M |
| Accumulated Other Comprehensive Income Loss | $-3.72M | $-1.44M | $6.05M | $-2.67M | $-4.90M |
| Other Total Stockholders Equity | $773.57M | $693.84M | $581.89M | $528.66M | $504.48M |
| Total Stockholders Equity | $67.83M | $138.18M | $117.74M | $185.40M | $238.56M |
| Total Equity | $67.83M | $138.18M | $117.74M | $185.40M | $238.56M |
| Total Liabilities and Stockholders Equity | $269.75M | $326.74M | $318.24M | $320.16M | $363.70M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $269.75M | $326.74M | $318.24M | $320.16M | $363.70M |
| Total Investments | $6.75M | $6.77M | $6.33M | $6.66M | $-213.72B |
| Total Debt | $4.05M | $89.26M | $92.25M | $23.73M | $22.25M |
| Net Debt | $-99.61M | $-40.30M | $-23.27M | $-113.97M | $-187.27M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $103.66M | $122.87M | $99.97M | $119.21M | $129.57M | $63.37M | $92.77M | $68.78M | $115.52M | $114.71M | $72.11M | $113.78M | $137.70M | $143.63M | $172.56M | $199.41M | $209.52M | $179.08M | $194.81M | $210.41M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $103.66M | $122.87M | $99.97M | $119.21M | $129.57M | $63.37M | $92.77M | $68.78M | $115.52M | $114.71M | $72.11M | $113.78M | $137.70M | $143.63M | $172.56M | $199.41M | $209.52M | $179.08M | $194.81M | $210.41M |
| Net Receivables | $10.63M | $3.28M | $5.18M | $24.09M | $23.41M | $32.41M | $40.72M | $44.16M | $21.33M | $28.60M | $22.29M | $19.94M | $35.02M | $22.16M | $25.39M | $19.40M | $38.48M | $33.73M | $31.21M | $34.80M |
| Inventory | $385.00K | $- | $- | $- | $- | $7.00M | $8.11M | $6.98M | $8.13M | $10.17M | $6.68M | $7.22M | $-12.63M | $8.84M | $6.51M | $6.37M | $7.08M | $4.25M | $7.32M | $3.84M |
| Other Current Assets | $8.85M | $12.89M | $5.62M | $6.01M | $6.64M | $7.75M | $9.65M | $8.54M | $17.49M | $11.73M | $10.01M | $9.20M | $10.52M | $11.14M | $9.09M | $11.31M | $7.65M | $5.07M | $9.19M | $5.80M |
| Total Current Assets | $123.52M | $139.05M | $110.77M | $149.30M | $159.62M | $103.53M | $143.14M | $121.48M | $154.34M | $155.04M | $104.41M | $142.93M | $183.24M | $176.93M | $207.04M | $230.13M | $272.58M | $217.88M | $235.21M | $251.01M |
| Property Plant Equipment Net | $135.65M | $149.43M | $145.95M | $149.93M | $156.24M | $153.01M | $157.32M | $156.86M | $154.09M | $136.42M | $137.69M | $134.06M | $126.29M | $115.71M | $108.83M | $98.78M | $87.12M | $73.41M | $53.73M | $51.99M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $821.00K | $951.00K | $969.00K | $1.04M | $1.12M | $1.87M | $2.00M | $2.05M | $2.08M | $1.98M | $2.20M | $2.44M | $2.57M | $2.66M | $2.82M | $2.87M | $2.97M | $810.36K | $774.73K | $762.28K |
| Goodwill and Intangible Assets | $821.00K | $951.00K | $969.00K | $1.04M | $1.12M | $1.87M | $2.00M | $2.05M | $2.08M | $1.98M | $2.20M | $2.44M | $2.57M | $2.66M | $2.82M | $2.87M | $2.97M | $810.36K | $774.73K | $762.28K |
| Long Term Investments | $6.75M | $6.77M | $6.77M | $7.83M | $7.85M | $6.33M | $6.33M | $6.33M | $6.33M | $6.66M | $6.66M | $6.66M | $6.66M | $6.67M | $6.67M | $6.67M | $- | $534.47K | $511.20K | $518.69K |
| Tax Assets | $- | $- | $- | $- | $131.42M | $- | $189.00K | $189.00K | $- | $171.00K | $181.00K | $194.00K | $- | $201.00K | $206.00K | $204.00K | $- | $203.25K | $194.32K | $191.20K |
| Other Non-Current Assets | $3.01M | $3.29M | $2.19M | $1.14M | $1.92M | $2.46M | $1.28M | $1.24M | $1.40M | $1.15M | $1.32M | $1.42M | $1.40M | $1.17M | $1.20M | $1.03M | $1.03M | $203.25K | $194.32K | $191.20K |
| Total Non-Current Assets | $146.23M | $160.44M | $155.88M | $159.94M | $298.55M | $163.66M | $167.12M | $166.66M | $163.90M | $146.38M | $148.05M | $144.77M | $136.92M | $126.41M | $119.72M | $109.55M | $91.12M | $75.16M | $55.40M | $53.66M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $269.75M | $299.49M | $266.65M | $309.24M | $458.17M | $267.19M | $310.26M | $288.14M | $318.24M | $301.41M | $252.46M | $287.69M | $320.16M | $303.34M | $326.77M | $339.68M | $363.70M | $293.05M | $290.61M | $304.67M |
| Account Payables | $23.59M | $29.50M | $21.40M | $21.22M | $16.04M | $20.77M | $28.50M | $29.75M | $16.62M | $21.69M | $18.11M | $18.50M | $15.35M | $11.42M | $11.64M | $7.90M | $7.13M | $5.20M | $3.09M | $7.29M |
| Short Term Debt | $4.05M | $8.37M | $8.42M | $4.19M | $4.19M | $4.09M | $8.25M | $8.04M | $3.88M | $7.32M | $7.27M | $7.26M | $6.75M | $6.56M | $6.35M | $5.55M | $2.58M | $4.23M | $4.28M | $3.92M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $4.83M | $5.11M | $3.50M | $3.77M | $2.93M | $7.92M | $12.06M | $13.69M | $15.12M | $18.88M | $21.20M | $20.19M | $21.82M | $23.00M | $24.88M | $25.60M | $23.54M | $23.72M | $23.00M | $20.93M |
| Other Current Liabilities | $28.32M | $16.44M | $13.69M | $18.36M | $43.92M | $30.73M | $23.00M | $29.62M | $46.45M | $24.47M | $20.92M | $19.55M | $24.21M | $18.65M | $14.39M | $14.47M | $44.43M | $13.47M | $16.35M | $10.88M |
| Total Current Liabilities | $60.78M | $59.42M | $47.01M | $47.54M | $67.08M | $63.51M | $71.80M | $81.10M | $82.07M | $72.36M | $67.50M | $65.50M | $68.13M | $59.63M | $57.25M | $53.52M | $54.15M | $46.61M | $46.72M | $43.03M |
| Long Term Debt | $80.74M | $82.55M | $83.35M | $84.19M | $85.07M | $86.10M | $87.08M | $87.75M | $88.36M | $88.30M | $19.06M | $20.77M | $20.36M | $21.26M | $22.36M | $20.00M | $19.67M | $17.13M | $18.56M | $19.17M |
| Deferred Revenue Non-Current | $57.58M | $- | $53.76M | $53.33M | $34.02M | $23.19M | $25.36M | $26.43M | $27.44M | $15.49M | $21.34M | $37.28M | $43.05M | $32.49M | $39.33M | $43.30M | $49.30M | $48.28M | $50.69M | $55.70M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $11.80M | $131.42M | $184.00K | $189.00K | $189.00K | $186.00K | $171.00K | $181.00K | $194.00K | $196.00K | $201.00K | $206.00K | $204.00K | $213.72K | $203.25K | $194.32K | $191.20K |
| Other Non-Current Liabilities | $2.82M | $61.78M | $2.49M | $2.44M | $2.40M | $2.32M | $2.30M | $2.45M | $2.44M | $2.42M | $2.40M | $2.67M | $3.03M | $1.92M | $1.90M | $1.86M | $1.81M | $1.74M | $1.68M | $1.65M |
| Total Non-Current Liabilities | $141.14M | $144.33M | $139.61M | $139.96M | $252.91M | $111.79M | $114.93M | $116.81M | $118.43M | $106.38M | $42.98M | $60.91M | $66.64M | $55.87M | $63.79M | $65.36M | $70.99M | $67.35M | $71.12M | $76.72M |
| Other Liabilities | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $201.92M | $203.75M | $186.61M | $187.50M | $319.99M | $175.31M | $186.74M | $197.92M | $200.50M | $178.74M | $110.49M | $126.41M | $134.76M | $115.50M | $121.05M | $118.88M | $125.14M | $113.96M | $117.85M | $119.74M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $261.03M | $451.75K | $330.53K | $- |
| Common Stock | $3.00K | $3.00K | $3.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $1.72K | $1.49K | $1.45K | $1.43K |
| Retained Earnings | $-702.02M | $-662.62M | $-623.29M | $-574.67M | $-554.23M | $-574.45M | $-530.15M | $-500.57M | $-470.20M | $-442.89M | $-405.61M | $-371.63M | $-340.59M | $-330.68M | $-304.73M | $-284.64M | $-261.03M | $-250.57M | $-244.14M | $-218.72M |
| Accumulated Other Comprehensive Income Loss | $-3.72M | $-4.85M | $-3.61M | $-3.13M | $-1.44M | $7.16M | $1.15M | $3.69M | $6.05M | $15.39M | $6.62M | $-739.00K | $-2.67M | $-2.91M | $-5.58M | $-5.17M | $-4.90M | $-1.45M | $2.67M | $2.15M |
| Other Total Stockholders Equity | $773.57M | $763.20M | $706.94M | $699.53M | $693.84M | $659.17M | $652.52M | $587.09M | $581.89M | $550.17M | $540.96M | $533.65M | $528.66M | $521.42M | $516.03M | $510.61M | $504.48M | $431.10M | $414.23M | $401.49M |
| Total Stockholders Equity | $67.83M | $95.74M | $80.04M | $121.73M | $138.18M | $91.89M | $123.53M | $90.22M | $117.74M | $122.67M | $141.97M | $161.28M | $185.40M | $187.84M | $205.72M | $220.79M | $238.56M | $179.09M | $172.77M | $184.92M |
| Total Equity | $67.83M | $95.74M | $80.04M | $121.73M | $138.18M | $91.89M | $123.53M | $90.22M | $117.74M | $122.67M | $141.97M | $161.28M | $185.40M | $187.84M | $205.72M | $220.79M | $238.56M | $179.09M | $172.77M | $184.92M |
| Total Liabilities and Stockholders Equity | $269.75M | $299.49M | $266.65M | $309.24M | $458.17M | $267.19M | $310.26M | $288.14M | $318.24M | $301.41M | $252.46M | $287.69M | $320.16M | $303.34M | $326.77M | $339.68M | $363.70M | $293.05M | $290.61M | $304.67M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $269.75M | $299.49M | $266.65M | $309.24M | $458.17M | $267.19M | $310.26M | $288.14M | $318.24M | $301.41M | $252.46M | $287.69M | $320.16M | $303.34M | $326.77M | $339.68M | $363.70M | $293.05M | $290.61M | $304.67M |
| Total Investments | $6.75M | $6.77M | $6.77M | $7.83M | $7.85M | $6.33M | $6.33M | $6.33M | $6.33M | $6.66M | $6.66M | $6.66M | $6.66M | $6.67M | $6.67M | $6.67M | $- | $534.47K | $511.20K | $518.69K |
| Total Debt | $84.80M | $86.73M | $87.56M | $88.38M | $89.26M | $90.19M | $91.20M | $91.77M | $92.25M | $91.96M | $22.70M | $24.40M | $23.73M | $24.54M | $25.53M | $22.77M | $22.25M | $19.24M | $20.69M | $21.14M |
| Net Debt | $-18.86M | $-36.14M | $-12.41M | $-30.83M | $-40.30M | $26.83M | $-1.57M | $22.99M | $-23.27M | $-22.74M | $-49.41M | $-89.38M | $-113.97M | $-119.09M | $-147.03M | $-176.64M | $-187.27M | $-159.84M | $-174.12M | $-189.27M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-147.79M | $-84.03M | $-129.62M | $-79.56M | $-57.99M |
| Depreciation and Amortization | $13.04M | $13.72M | $8.72M | $7.87M | $4.17M |
| Deferred Income Tax | $- | $- | $- | $6.36M | $-3.21M |
| Stock Based Compensation | $25.19M | $27.72M | $28.62M | $20.78M | $18.42M |
| Change in Working Capital | $- | $-983.00K | $9.62M | $31.28M | $-32.64M |
| Accounts Receivables | $6.33M | $4.83M | $1.03M | $16.39M | $-15.40M |
| Inventory | $-387.00K | $- | $- | $9.03M | $-3.24M |
| Accounts Payables | $10.74M | $2.33M | $3.74M | $13.35M | $1.57M |
| Other Working Capital | $- | $-8.14M | $4.85M | $-7.49M | $-15.56M |
| Other Non Cash Items | $5.07M | $-61.80M | $9.55M | $2.74M | $7.29M |
| Net Cash Provided by Operating Activities | $-104.50M | $-105.36M | $-73.10M | $-10.53M | $-63.97M |
| Investments in Property Plant and Equipment | $-4.96M | $-20.17M | $-44.96M | $-55.22M | $-37.02M |
| Acquisitions Net | $- | $- | $- | $-6.50M | $- |
| Purchases of Investments | $- | $- | $- | $-6.50M | $- |
| Sales Maturities of Investments | $- | $- | $- | $21.87M | $- |
| Other Investing Activities | $28.43M | $54.21M | $- | $-15.37M | $-16.10M |
| Net Cash Used for Investing Activities | $23.48M | $34.03M | $-44.96M | $-61.72M | $-37.02M |
| Debt Repayment | $- | $- | $75.00M | $-1.00K | $-23.00K |
| Common Stock Issued | $59.39M | $91.95M | $25.00M | $1.71M | $87.05M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-4.86M | $-7.93M | $-4.80M | $1.71M | $-4.30M |
| Net Cash Used Provided by Financing Activities | $54.53M | $84.02M | $95.20M | $1.71M | $82.73M |
| Effect of Forex Changes on Cash | $1.50M | $2.44M | $674.00K | $-1.28M | $424.44K |
| Net Change in Cash | $-24.98M | $15.13M | $-22.19M | $-71.82M | $-17.84M |
| Cash at End of Period | $105.67M | $130.65M | $115.52M | $137.70M | $209.52M |
| Cash at Beginning of Period | $130.65M | $115.52M | $137.70M | $209.52M | $227.36M |
| Operating Cash Flow | $-104.50M | $-105.36M | $-73.10M | $-10.53M | $-63.97M |
| Capital Expenditure | $-4.96M | $-20.17M | $-44.96M | $-55.22M | $-37.02M |
| Free Cash Flow | $-109.45M | $-125.54M | $-118.06M | $-65.75M | $-100.99M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-39.40M | $-39.33M | $-48.62M | $-20.44M | $20.21M | $-44.30M | $-29.58M | $-30.36M | $-27.31M | $-37.28M | $-33.97M | $-31.05M | $-9.91M | $-25.95M | $-20.09M | $-23.62M | $-10.46M | $-6.43M | $-25.42M | $-15.68M |
| Depreciation and Amortization | $2.92M | $3.26M | $3.22M | $3.27M | $3.91M | $3.48M | $3.25M | $3.09M | $2.49M | $2.03M | $2.08M | $2.12M | $2.06M | $2.04M | $2.02M | $1.76M | $1.35M | $1.07M | $940.32K | $815.42K |
| Deferred Income Tax | $- | $- | $- | $- | $-10.54M | $8.77M | $-1.91M | $- | $- | $- | $- | $- | $1.76M | $3.37M | $-251.00K | $1.58M | $-2.56M | $-1.87M | $450.03K | $764.25K |
| Stock Based Compensation | $6.12M | $6.30M | $5.81M | $6.96M | $6.96M | $7.05M | $7.27M | $6.43M | $6.80M | $6.94M | $7.30M | $7.58M | $5.42M | $5.34M | $5.20M | $4.82M | $3.94M | $3.74M | $5.06M | $5.68M |
| Change in Working Capital | $1.45M | $7.37M | $19.16M | $1.66M | $19.90M | $322.00K | $-8.28M | $-12.93M | $17.67M | $-5.46M | $-13.39M | $10.81M | $17.03M | $-2.08M | $-8.18M | $24.51M | $-21.48M | $-5.68M | $-1.63M | $-3.85M |
| Accounts Receivables | $-3.78M | $-17.35M | $18.95M | $-1.60M | $7.31M | $10.35M | $3.58M | $-14.14M | $3.18M | $-7.94M | $-3.38M | $9.17M | $-5.09M | $818.00K | $-6.10M | $26.76M | $-11.68M | $-2.59M | $3.57M | $-4.71M |
| Inventory | $- | $- | $- | $- | $4.01M | $2.75M | $-6.76M | $- | $- | $- | $- | $- | $3.50M | $2.67M | $2.11M | $751.00K | $-7.10M | $813.41K | $1.93M | $1.12M |
| Accounts Payables | $-3.29M | $-5.67M | $472.00K | $5.20M | $-3.06M | $-7.68M | $-1.57M | $14.64M | $-4.89M | $4.92M | $-903.00K | $4.61M | $9.45M | $1.38M | $926.00K | $1.59M | $1.08M | $1.19M | $-4.65M | $3.94M |
| Other Working Capital | $8.52M | $30.39M | $-269.00K | $-1.93M | $15.66M | $-5.10M | $-3.54M | $-13.43M | $19.38M | $-2.44M | $-10.76M | $-2.97M | $9.17M | $-6.95M | $-5.12M | $-4.59M | $-3.79M | $-5.09M | $-2.47M | $-4.21M |
| Other Non Cash Items | $5.63M | $-2.63M | $976.00K | $-18.28M | $-55.00M | $263.00K | $238.00K | $-3.62M | $-15.92M | $13.06M | $-258.00K | $2.24M | $2.47M | $104.00K | $39.00K | $35.00K | $-351.96K | $34.46K | $7.72M | $-110.53K |
| Net Cash Provided by Operating Activities | $-23.28M | $-25.02M | $-19.46M | $-36.74M | $-14.55M | $-24.41M | $-29.01M | $-37.39M | $-16.27M | $-20.73M | $-27.81M | $-8.30M | $18.83M | $-17.18M | $-21.26M | $9.09M | $-29.56M | $-9.14M | $-12.88M | $-12.38M |
| Investments in Property Plant and Equipment | $-1.22M | $-730.00K | $-1.33M | $-1.68M | $-3.03M | $-3.56M | $-4.97M | $-8.61M | $-8.49M | $-10.01M | $-14.00M | $-12.46M | $-24.37M | $-11.90M | $-5.58M | $-13.37M | $-10.23M | $-19.83M | $-2.92M | $-4.04M |
| Acquisitions Net | $- | $-584.00K | $- | $29.02M | $54.21M | $- | $- | $- | $- | $- | $- | $- | $-1.00M | $- | $- | $-5.50M | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-1.00M | $- | $- | $-5.50M | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $29.02M | $54.21M | $- | $- | $- | $- | $- | $- | $- | $-1.00M | $- | $- | $-14.37M | $-2.22M | $-13.88M | $- | $- |
| Net Cash Used for Investing Activities | $-1.22M | $-1.31M | $-1.33M | $27.34M | $51.18M | $-3.56M | $-4.97M | $-8.61M | $-8.49M | $-10.01M | $-14.00M | $-12.46M | $-25.37M | $-11.90M | $-5.58M | $-18.87M | $-10.23M | $-19.83M | $-2.92M | $-4.04M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $4.00K | $-5.00K | $-3.71K | $-3.00K | $-6.00K | $-10.00K |
| Common Stock Issued | $4.25M | $51.94M | $1.61M | $1.59M | $30.00M | $- | $61.95M | $- | $- | $- | $- | $192.00K | $1.29M | $54.00K | $219.00K | $141.00K | $73.89M | $13.16M | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $-1.23M | $- | $- | $- | $-2.77M | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-11.00K | $-1.98M | $-9.00K | $-2.86M | $-2.29M | $-288.00K | $-4.00M | $-1.23M | $24.83M | $72.95M | $- | $-2.58M | $1.29M | $54.00K | $219.00K | $141.00K | $-4.45M | $-28.19K | $385 | $174.81K |
| Net Cash Used Provided by Financing Activities | $4.24M | $49.96M | $1.60M | $-1.27M | $27.71M | $-404.00K | $57.95M | $-1.23M | $24.83M | $72.95M | $- | $-2.58M | $1.29M | $54.00K | $223.00K | $136.00K | $69.44M | $13.13M | $-5.62K | $164.81K |
| Effect of Forex Changes on Cash | $889.00K | $383.00K | $-58.00K | $287.00K | $1.90M | $12.00K | $29.00K | $496.00K | $736.00K | $386.00K | $134.00K | $-582.00K | $-685.00K | $112.00K | $-241.00K | $-464.00K | $546.69K | $366.72K | $-173.88K | $-315.08K |
| Net Change in Cash | $-19.36M | $24.00M | $-19.24M | $-10.36M | $66.20M | $-28.37M | $23.99M | $-46.73M | $810.00K | $42.60M | $-41.67M | $-23.92M | $-5.93M | $-28.92M | $-26.85M | $-10.11M | $30.19M | $-15.48M | $-15.98M | $-16.57M |
| Cash at End of Period | $105.67M | $125.03M | $99.97M | $119.21M | $129.57M | $64.40M | $92.77M | $68.78M | $115.52M | $114.71M | $72.11M | $113.78M | $137.70M | $143.63M | $172.56M | $199.41M | $209.52M | $179.33M | $194.81M | $210.79M |
| Cash at Beginning of Period | $125.03M | $99.97M | $119.21M | $129.57M | $63.37M | $92.77M | $68.78M | $115.52M | $114.71M | $72.11M | $113.78M | $137.70M | $143.63M | $172.56M | $199.41M | $209.52M | $179.33M | $194.81M | $210.79M | $227.36M |
| Operating Cash Flow | $-23.28M | $-25.02M | $-19.46M | $-36.74M | $-14.55M | $-24.41M | $-29.01M | $-37.39M | $-16.27M | $-20.73M | $-27.81M | $-8.30M | $18.83M | $-17.18M | $-21.26M | $9.09M | $-29.56M | $-9.14M | $-12.88M | $-12.38M |
| Capital Expenditure | $-1.22M | $-730.00K | $-1.33M | $-1.68M | $-3.03M | $-3.56M | $-4.97M | $-8.61M | $-8.49M | $-10.01M | $-14.00M | $-12.46M | $-24.37M | $-11.90M | $-5.58M | $-13.37M | $-10.23M | $-19.83M | $-2.92M | $-4.04M |
| Free Cash Flow | $-24.49M | $-25.75M | $-20.79M | $-38.42M | $-17.58M | $-27.98M | $-33.99M | $-46.00M | $-24.76M | $-30.74M | $-41.81M | $-20.76M | $-5.54M | $-29.09M | $-26.84M | $-4.28M | $-39.80M | $-28.98M | $-15.80M | $-16.42M |
MeiraGTx Holdings plc Dividends
Explore MeiraGTx Holdings plc's dividend history, including dividend yield, payout ratio, and historical payments.
MeiraGTx Holdings plc News
Read the latest news about MeiraGTx Holdings plc, including recent articles, headlines, and updates.
MeiraGTx Holdings: Gaining Regulatory Focus
MeiraGTx (MGTX) develops gene therapies for ocular diseases, Parkinson's Disease, and xerostomia, with multiple assets in advanced clinical stages showing promising efficacy and safety data. MGTX uses AAV5 capsid vectors and riboswitch technology to deliver gene therapies, aiming for safer and more controlled treatments compared to earlier approaches. Financially, MGTX has a strong cash position bolstered by a $200mn deal with Hologen, providing a substantial runway for continued development.
MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars
On Thursday, MeiraGTx Holdings plc MGTX announced a broad strategic collaboration with Hologen Limited, a developer of multi-modal generative AI foundation models of real-world clinical data for clinical medicine and pharmaceutical drug development.
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates
- Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint venture, Hologen Neuro AI Ltd, with a further $230 million in capital committed to initially focus on expediting Phase 3 clinical development of AAV-GAD for Parkinson's disease - MeiraGTx and Hologen have created the first neuro-AI clinical drug development company to transform the discovery and development of therapies targeting CNS circuitry in neurodegenerative and neuropsychiatric disorders - Announced positive data from randomized, double blind, sham-controlled clinical bridging study of AAV-GAD for the treatment of Parkinson's disease demonstrating significant benefits in Unified Parkinson's Disease Rating Scale (UPDRS) Part 3 and Parkinson's Disease Questionnaire (PDQ-39) - Granted FDA Regenerative Medicine Advanced Therapy (RMAT) designation for AAV2-hAQP1 for the treatment of Grade 2/3 radiation-induced xerostomia (RIX) - Efficacy data of rAAV8.hRKp.AIPL1 for the treatment of LCA4 published in The Lancet ; unprecedented responses observed in 100% of LCA4 children and MeiraGTx intends to submit a Marketing Authorization Application (MAA) under exceptional circumstances with MHRA, and follow a parallel pathway to BLA with the FDA this year - Received FDA Rare Pediatric Disease Designations (RPDD) for four potential therapies for rare inherited retinal diseases (IRDs) including rAAV8.hRKp.AIPL1 for LCA4 - Received from HPRA and MHRA additional clinical and commercial licensures in Ireland and UK for Shannon and London GMP viral vector manufacturing facilities as well as QC facilities LONDON and NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the fourth quarter and full-year ended December 31, 2024, and provided a corporate update. “MeiraGTx demonstrated excellent execution in 2024, marked by significant advancements across each of our late stage clinical programs as well as our end-to-end manufacturing capabilities, achieving multiple positive clinical and regulatory milestones,” said Alexandria Forbes, Ph.D.
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process
- MeiraGTx to receive $200 million in upfront cash consideration - MeiraGTx and Hologen will form a joint venture, Hologen Neuro AI Ltd, with an additional $230 million committed capital from Hologen to fund 100% of the development of AAV-GAD for Parkinson's disease through to commercialization, as well as other potential pipeline products - MeiraGTx will enter into clinical and commercial supply agreements with Hologen Neuro AI Ltd to manufacture AAV-GAD and other locally delivered CNS genetic medicines - Hologen will also fund a portion of MeiraGTx's manufacturing operations and will own a minority stake in MeiraGTx's manufacturing subsidiary LONDON and NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration with Hologen Limited, a world-leading developer of multi-modal generative AI foundation models of real-world clinical data for clinical medicine and pharmaceutical drug development. MeiraGTx will receive $200 million in upfront cash at closing and MeiraGTx and Hologen are forming a joint venture, called Hologen Neuro AI Ltd.
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
LONDON and NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the publication of results from the first-in-human interventional study to treat children with AIPL1-associated severe retinal dystrophy. The data were published in The Lancet in a paper titled, "Gene therapy in children with AIPL1-associated severe retinal dystrophy: an open-label, first-in-human interventional study". This paper presents data from the first 4 children treated unilaterally with rAAV8.hRKp.AIPL1. A further 7 children with LCA4 were treated bilaterally with rAAV8.hRKp.AIPL1 demonstrating similarly remarkable effects on vision, with all 11 of the 11 children treated who were blind at birth now having visual acuity in the treated eyes.
MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder Value
MeiraGTx Holdings plc is advancing AAV-AIPL1 for AIPL1-associated Leber congenital amaurosis 4, with a near-term BLA filing in the UK under Exceptional Circumstance possible. Bota-vec, developed with Janssen, could see a BLA filing for X-linked Retinitis Pigmentosa in 2025. Initiation of phase 3 study, using AAV-GAD for the treatment of patients with Parkinson's Disease, expected in 2025.
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company's proprietary technology platforms MeiraGTx has recently received Rare Pediatric Disease Designation (RPDD) for four inherited retinal diseases (IRDs) reflecting the transformative therapeutic potential of the Company's proprietary technology platforms
MeiraGTx Holdings: Behind The Recent Rally
MeiraGTx Holdings plc has rallied over 40% following promising Parkinson's disease data, with significant potential in its Riboswitch platform for gene expression control. The company's diverse pipeline includes gene therapies for salivary gland conditions, neurological disorders, and inherited retinal diseases, with multiple BLAs expected from 2024-2027. Recent strategic deals with J&J and Sanofi have bolstered MeiraGTx's financial position, providing a runway into 2Q26 and highlighting strong investor confidence.
MeiraGTx: Positive PD Data Moves Needle Forward For Regulatory Meetings
MeiraGTx Holdings plc's GAD gene therapy for Parkinson's Disease shows promising phase 1/2 results, with significant improvements in UPDRS Part 3 and PDQ-39 scores. The company plans to discuss phase 3 study designs with regulatory agencies in Q4 2024, potentially initiating late-stage studies in 2025. MeiraGTx secured $50 million in funding, including a $30 million equity investment from Sanofi, enhancing its financial stability for future developments.
MeiraGTx Announces Poster Presentation on a Potential Treatment for MC4R Genetic Deficiency at the 2024 Society for Neuroscience Conference
Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency Results indicate a potent and effective locally delivered AAV-BDNF gene therapy for the treatment of obesity caused by MC4R deficiency
MeiraGTx Announces $50 Million Offering of Ordinary Shares led by Sanofi and Reports Second Quarter 2024 Financial and Operational Results
- Positive data from the Phase 1 AQUAx study in radiation-induced xerostomia (RIX) presented at the American Academy of Oral Medicine 2024 annual meeting (AAOM) showed meaningful improvements in patient-reported outcomes and saliva production with AAV2-hAQP1 treatment
MeiraGTx Announces Pricing of Offering of Ordinary Shares Led by Sanofi
LONDON and NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicine company, today announced the pricing of an underwritten offering of 12,500,000 of its ordinary shares at an offering price of $4.00 per share. Gross proceeds to MeiraGTx from the offering are expected to be $50 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by MeiraGTx.
MeiraGTx: A Very Attractive Longer-Term Play, With Potential Near-Term Catalysts
Bota-vec sale to JNJ/Janssen is complete – cash & future milestones from the deal should carry MeiraGTx through the next catalysts. The partnership with Sanofi strengthens the balance sheet and helps validate technology platforms. MGTX is no longer just an ocular GTx (gene therapy) company - its GTx for radiation-induced xerostomia has a high potential for success.
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held from April 16-20, 2024, at the Hyatt Regency Grand Cypress in Orlando, FL.
MeiraGTx: Bota-Vec Program Advancing With Milestones Being Met
Positive results achieved in phase 1/2 MGT009 study using bota-vec for the treatment of patients with XLRP; Patients given this gene therapy achieved meaningful improvement of vision. Enrollment completed in ongoing phase 3 LUMEOS study, using bota-vec for the treatment of patients with XLRP; Potential results could be released end of 2024 or in early 2025. The global Retinitis Pigmentosa market size is expected to reach $20.47 billion by 2029; It is said that 10% to 15% of RP patients have XLRP.
Wall Street Analysts Think MeiraGTx Holdings PLC (MGTX) Could Surge 217.92%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 217.9% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe MeiraGTx Holdings PLC (MGTX) Could Rally 221.78%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 221.8% in MeiraGTx Holdings PLC (MGTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
MeiraGTx Announces Asset Purchase Agreement Involving its AAV-RPGR Collaboration for up to $415 million
- MeiraGTx enters into an Asset Purchase Agreement related to botaretigene sparoparvovec (bota-vec, formerly AAV-RPGR) for the treatment of X-linked retinitis pigmentosa (XLRP) for a total of up to $415 million
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for MGTX.